Cancer immunotherapy has seen significant advancements through the targeted inhibition of specific immune checkpoints, particularly cytotoxic T lymphocyte antigen-4 (CTLA-4) and PD-1/PD-L1. The gene discussed is CTLA4; the disease is cancer.